Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Mar;59(3):680-93.
doi: 10.1161/HYPERTENSIONAHA.111.181867. Epub 2012 Jan 23.

Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function

Affiliations
Comparative Study

Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function

Yingmei Zhang et al. Hypertension. 2012 Mar.

Erratum in

  • Hypertension. 2014 Apr;63(4):e92

Retraction in

Abstract

Obesity is often associated with reduced plasma insulin-like growth factor 1 (IGF-1) levels, oxidative stress, mitochondrial damage, and cardiac dysfunction. This study was designed to evaluate the impact of IGF-1 on high-fat diet-induced oxidative, myocardial, geometric, and mitochondrial responses. FVB and cardiomyocyte-specific IGF-1 overexpression transgenic mice were fed a low- (10%) or high-fat (45%) diet to induce obesity. High-fat diet feeding led to glucose intolerance, elevated plasma levels of leptin, interleukin 6, insulin, and triglyceride, as well as reduced circulating IGF-1 levels. Echocardiography revealed reduced fractional shortening, increased end-systolic and end-diastolic diameter, increased wall thickness, and cardiac hypertrophy in high-fat-fed FVB mice. High-fat diet promoted reactive oxygen species generation, apoptosis, protein and mitochondrial damage, reduced ATP content, cardiomyocyte cross-sectional area, contractile and intracellular Ca(2+) dysregulation (including depressed peak shortening and maximal velocity of shortening/relengthening), prolonged duration of relengthening, and dampened intracellular Ca(2+) rise and clearance. Western blot analysis revealed disrupted phosphorylation of insulin receptor and postreceptor signaling molecules insulin receptor substrate 1 (tyrosine/serine phosphorylation), Akt, glycogen synthase kinase 3β, forkhead transcriptional factors, and mammalian target of rapamycin, as well as downregulated expression of mitochondrial proteins peroxisome proliferator-activated receptor-γ coactivator 1α and uncoupling protein 2. Intriguingly, IGF-1 mitigated high-fat-diet feeding-induced alterations in reactive oxygen species, protein and mitochondrial damage, ATP content, apoptosis, myocardial contraction, intracellular Ca(2+) handling, and insulin signaling but not whole body glucose intolerance and cardiac hypertrophy. Exogenous IGF-1 treatment also alleviated high-fat diet-induced cardiac dysfunction. Our data revealed that IGF-1 alleviates high-fat diet-induced cardiac dysfunction despite persistent cardiac remodeling, possibly because of preserved cell survival, mitochondrial function, and insulin signaling.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of cardiac IGF-1 overexpression on glucose tolerance, ROS production, apoptosis, ATP production, protein and mitochondrial damage following low fat (LF) or high fat (HF)-diet feeding. A: IPGTT displaying serum glucose levels following glucose challenge (2 g glucose/kg body weight); B: Area under the curve (AUC) calculated from IPGTT curves; C: Cardiomyocyte ROS production; D: Myocardial protein carbonyl formation; E: Myocyte Caspase-3 activity; F: Myocardial aconitase activity; G: Myocardial ATP content; and H. Mitochondrial and cytosolic Cytochrome C expression from myocardium (normalized to the loading control GAPDH). Inset: Representative gel blots of mitochondrial and cytosolic cytochrome C as well as GAPDH using specific antibodies. Mean ± SEM, n = 7–10 mice/group, *p < 0.05 vs. FVB-LF group, #p < 0.05 vs. FVB-HF group, †p < 0.05 vs. IGF-LF group.
Fig. 2
Fig. 2
Contractile properties of cardiomyocytes from LF and HF-fed FVB and IGF-1 transgenic mouse hearts. A: Representative cell shortening traces in FVB groups; B: Representative cell shortening traces in IGF groups; C: Resting cell length; D: Peak shortening (normalized to cell length); E: Maximal velocity of shortening (+ dL/dt); F: Maximal velocity of relengthening (− dL/dt); G: Time-to-PS (TPS); and H: Time-to-90% relengthening (TR90). Mean ± SEM, n = 80 cells from 3–4 mice/group, *p < 0.05 vs. FVB-LF group, #p < 0.05 vs. FVB-HF group.
Fig. 3
Fig. 3
Intracellular Ca2+ transients and stimulus frequency response in cardiomyocytes from LF and HF-fed FVB and IGF-1 mouse hearts. A: Peak shortening (PS) in response to increasing stimulus frequency (0.1 – 5.0 Hz). Each point represents PS normalized to that of 0.1 Hz of the same cell; B: Representative intracellular Ca2+ transient traces in LF or HF-fed groups; C: Resting fura-2 fluorescence intensity (FFI); D: Electrically-stimulated rise in FFI (ΔFFI); E: Peak FFI; and F: Intracellular Ca2+ decay rate. Mean ± SEM, n = 68 cells (23–25 cells for panel A) from 3–4 mice/group, *p < 0.05 vs. FVB-LF group, #p < 0.05 vs. FVB-HF group.
Fig. 4
Fig. 4
Effect of IGF-1 overexpression on myocardial apoptosis and hypertrophy following LF or HF feeding using TUNEL and FITC-conjugated Lectin staining, respectively. All nuclei were stained with DAPI (blue) in panels B (FVB-LF), D (FVB-HF), F (IGF-LF) and H (IGF-HF). TUNEL-positive nuclei were visualized with fluorescein (green) in panels A (FVB-LF), C (FVB-HF), E (IGF-LF) and G (IGF-HF). Original magnification = 400×. Quantified data are shown in panel I; J: FITC-conjugated Lectin immunostaining depicting transverse sections of left ventricular myocardium (×400); and K: Quantitative analysis of cardiomyocyte cross-sectional area. Mean ± SEM, n = 15 and 10 fields from 3 mice per group for panel I and K, respectively, *p < 0.05 vs. FVB-LF group; #p < 0.05 vs. FVB-HF group, †p < 0.05 vs. FVB-LF group.
Fig. 5
Fig. 5
Western blot analysis of the mitochondrial proteins UCP-2 and PGC1α as well as the Ca2+ regulatory proteins SERCA2a, Na+-Ca2+ exchanger (NCX) and phospholamban in myocardium from LF and HF-fed FVB and IGF-1 mice. A: Representative gel blots of UCP-2, PGC1α, SERCA2a, Na+-Ca2+ exchanger, phospholamban and GAPDH (loading control) using specific antibodies; B: UCP-2; C: PGC1α; D: SERCA2a; E: Na+-Ca2+ exchanger; and F: Phospholamban. All proteins were normalized to the loading control GAPDH. Mean ± SEM, n = 8–9 mice per group, *p <0.05 vs. FVB-LF group, #p < 0.05 vs. FVB-HF group.
Fig. 6
Fig. 6
Western blot analysis of pan and phosphorylated insulin receptor β or IGF-1 receptor β in cardiomyocytes from LF and HF-fed FVB and IGF-1 mice. A: Insulin receptor β expression; B: Basal and insulin/IGF-1-stimulated (at 100 nM for 15 min) tyrosine phosphorylation of insulin receptor β; C: IGF-1 receptor β expression; D: Basal and insulin/IGF-1-stimulated (at 100 nM for 15 min) tyrosine phosphorylation of IGF-1 receptor β; E: Tyrosine phosphorylation of IRS (Tyr1146) normalized to pan IRS; and F: Serine phosphorylation of IRS (Ser307) normalized to pan IRS; Insets: Representative gel blots of pan and phosphorylated insulin receptor β, IGF receptor β, and IRS using respective specific antibodies. Protein expressions were normalized to that of FVB-LF group for immunoprecipitation studies. pY denotes anti-phosphotyrosine antibody; IP and IB represent immunoprecipitation and immunoblot, respectively; Mean ± SEM, n = 5–7 mice per group, *p <0.05 vs. un-stimulated FVB-LF group, †p < 0.05 vs. insulin-stimulated FVB-LF group, #p < 0.05 vs. respective FVB-HF group.
Fig. 7
Fig. 7
Phosphorylation of Akt, GSK3β, Foxo3a and mTOR with or without insulin stimulation (100 nM for 15 min) in cardiomyocytes from LF and HF-fed FVB and IGF-1 mice. A: pAkt-to-Akt ratio; B: pGSK3β-to-GSK3β ratio; C: pFoxo3a-to-Foxo3a ratio; and D: pmTOR-to-mTOR ratio. Insets: Representative gel blots of pan and phosphorylated Akt, GSK3β, Foxo3a and mTOR (GAPDH was used as loading control) using specific antibodies; Mean ± SEM, n = 6–9 isolations per group, *p < 0.05 vs. un-stimulated FVB-LF group, †p < 0.05 vs. insulin-stimulated FVB-LF group, #p < 0.05 vs. respective FVB-HF group.
Fig. 8
Fig. 8
Influence of IGF-1 on palmitate-induced responses of glucose uptake, aconitase activity, cell survival and cardiomyocyte contractile properties. Cardiomyocytes from control FVB mice maintained in DEME medium at 37°C were exposed to palmitate (100 µM) in the absence or presence of IGF-1 (10 nM), the mitochondrial uncoupler FCCP (1 µM), or the GSK3β inhibitor SB216763 (10 µM) for 6 hrs prior to assessment of mechanical and biochemical properties A: Insulin (10 nM)-stimulated cardiomyocyte glucose uptake; B: Myocardial aconitase activity; C: Cardiomyocyte survival rate; D: Peak shortening (% of cell length); E: Maximal velocity of shortening and relengthening (± dL/dt); and F: Time-to-90% relengthening (TR90); Mean ± SEM, n = 5 isolations or 60 cells, *p < 0.05 vs. Control group, #p < 0.05 vs. Palmitate group.

Comment in

  • Heart smart insulin-like growth factor 1.
    Marsh SA, Davidoff AJ. Marsh SA, et al. Hypertension. 2012 Mar;59(3):550-1. doi: 10.1161/HYPERTENSIONAHA.111.188441. Epub 2012 Jan 23. Hypertension. 2012. PMID: 22275529 No abstract available.

Similar articles

Cited by

References

    1. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation. 2002;105:2923–2928. - PubMed
    1. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia. 2006;49:1434–1446. - PubMed
    1. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation. 1981;64:477–482. - PubMed
    1. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med. 2010;88:993–1001. - PMC - PubMed
    1. Zhang Y, Ren J. Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension. 2011;57:148–150. - PubMed

Publication types

MeSH terms

Substances